Related Experiment Video
Updated: May 5, 2026

In Vivo Imaging Systems IVIS Detection of a Neuro-Invasive Encephalitic Virus
Published on: December 2, 2012
Controversies in COVID-19: Diagnostic Evaluation and Management in Neuro-COVID
Jordan Yakoby1, Juda Zurndorfer2
1Department of Nursing, New York School of Career and Applied Studies, Touro University, 3 Times Square, 3rd Floor, Room 322, New York, NY, 10044, USA. jyakoby@touro.edu.
Abstract:
SARS-CoV-2 is a virus in the coronavirus family originating out of Wuhan, China clinically known as COVID-19. While traditionally thought of as a respiratory virus, COVID-19 can have a multi-organ impact due to its invasion and widespread distribution throughout the body and via the angiotensin converting enzyme. Neurologic events due to COVID-19 are common, especially in the critically ill, and are called Neuro-COVID. Among these events are peripheral and central nervous system diseases such as Guillain-Barré, ischemic stroke, and various types of encephalitis. The impact of Neuro-COVID is devastating and is often far more severe than its non-COVID-19 form. Immunosuppressive or immunomodulatory therapy is often a mainstay of treatment, such as for encephalitis and Guillain-Barré, respectively, while management may fall in line with conventional processes in most cases, such as ischemic stroke. Much remains to be studied about the evaluation and management of Neuro-COVID.
Related Concept Videos
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Acute Pyelonephritis II: Diagnostic Studies and Management
Viral Meningitis
Encephalitis ll: Pathophysiology
Brain Abscess l: Introduction

